BrainScope Ahead 100

The BrainScope Ahead 100 is a portable EEG-based device that analyzes quantitative metrics from frontal brain activity to classify adult patients with recent, mild closed head injuries for the likelihood of structural brain injury. Its purpose is to supplement clinical judgment and reduce unnecessary CT scans by offering a highly sensitive, moderately specific screening tool.

The BrainScope Ahead 100 is a portable medical device designed for the assessment of adult patients, aged 18 to 80, who have sustained a closed head injury within the preceding 24 hours and present with a mild Glasgow Coma Scale (GCS) score of 13 to 15. Its core methodology involves recording electroencephalography (EEG) data specifically from the frontal region of the brain. This data is then processed to calculate a range of quantitative metrics, including but not limited to power spectrum, coherence between different brain regions, asymmetry in brain activity, and fractal dimension. Based on these complex electrophysiological measurements, the device's algorithm classifies patients as either 'Negative' or 'Positive' for the likelihood of a structural brain injury, thereby aiding clinicians in the critical decision of whether a computed tomography (CT) scan is warranted. The development of the BrainScope Ahead 100's diagnostic algorithm was informed by data collected from trauma patients who had undergone CT scans, allowing for correlation between EEG findings and confirmed structural injuries. This development process yielded a device with reported performance characteristics of approximately 95% sensitivity in detecting structural brain injuries and around 68% specificity in correctly identifying patients without such injuries. It is intended to function as an adjunct to standard clinical evaluation, not a replacement. The primary aim of the BrainScope Ahead 100 is to reduce the frequency of unnecessary head CT scans and their associated costs and radiation exposure, while concurrently ensuring that patients who do have structural brain injuries and require further imaging are promptly and accurately identified for appropriate medical management.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the BrainScope Ahead 100's performance (sensitivity and specificity) vary across the spectrum of GCS scores (13, 14, and 15) within its indicated patient population?; What specific quantitative EEG features (e.g., particular frequency bands for power, specific electrode pair coherences) are most heavily weighted in the device's algorithm for classifying structural brain injury?; Are there studies evaluating the impact of confounding factors, such as recent alcohol or drug use, or pre-existing neurological conditions, on the accuracy of the BrainScope Ahead 100's classifications?; What is the learning curve for clinicians to effectively integrate the BrainScope Ahead 100 into their workflow, and what is the average time saved per patient encounter where a CT scan is avoided?; Beyond the binary Negative/Positive classification, does the device provide any graded output or confidence score that could offer more nuanced guidance to clinicians, especially in borderline cases?